Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Milestone Pharmaceuticals (Nasdaq: MIST) granted a total of 123,000 stock options under its 2021 Inducement Plan as material inducements for three new hires. The options were granted with an April 1, 2026 grant date and an exercise price of $1.31, equal to the closing share price on that date. The options vest over four years (25% after one year, then monthly over 36 months) and are subject to continuous service and the Plan's terms pursuant to Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- None.
News Market Reaction – MIST
On the day this news was published, MIST gained 5.34%, reflecting a notable positive market reaction. Argus tracked a peak move of +7.6% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $8M to the company's valuation, bringing the market cap to $164.72M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MIST is up 10.08%, while peers are mixed: ACOG +8.36%, KYTX +1.5%, VTYX and CYBN near flat, and GLSI -3.69%. This pattern points to stock-specific dynamics rather than a broad biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Formulary access win | Positive | +17.8% | CARDAMYST added to Express Scripts commercial national formularies, broadening access. |
| Mar 20 | Earnings and launch | Positive | -20.0% | Reported CARDAMYST approval, U.S. launch and liquidity runway alongside 2025 results. |
| Mar 16 | Clinical data update | Positive | -0.9% | ACC.26 data showing minimal blood pressure effects and low hypotension/syncope rates. |
| Mar 12 | Earnings call notice | Neutral | +2.3% | Announcement of date and access details for Q4 and full-year 2025 results call. |
| Feb 26 | Conference participation | Neutral | -0.6% | Planned presentation at TD Cowen health care conference with webcast access. |
Recent news with clear commercial or clinical positives has sometimes seen divergent price reactions, including a notable selloff on positive earnings and launch updates.
Over the last few months, Milestone has shifted into a commercial-stage story. FDA approval and U.S. launch of CARDAMYST, plus $106.0M year-end cash and pro forma liquidity near $200M, framed a growth-focused but loss-making profile. Subsequent updates included conference presentations, formulary inclusion by Express Scripts, and routine event notices. The current inducement option grants follow a series of equity awards to executives, fitting into an ongoing pattern of equity-based compensation as the company builds its commercial organization.
Market Pulse Summary
The stock moved +5.3% in the session following this news. A strong positive reaction aligns with Milestone’s recent pattern, where news around CARDAMYST and commercial execution has coincided with notable moves, such as the 17.82% gain on formulary inclusion. This option grant under an inducement plan adds modest incremental overhang but also signals ongoing hiring. Investors monitoring sustainability would weigh prior divergences, like the -20% move on positive earnings and launch details, against current enthusiasm.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
equity awards financial
stock options financial
inducement plan financial
AI-generated analysis. Not financial advice.
MONTREAL and CHARLOTTE, N.C., April 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 123,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of three new employees.
The Options have a grant date of April 1, 2026, and an exercise price of
The Option awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Plan and its standard forms of grant agreements thereunder.
The foregoing equity award was granted as an inducement material to the employees entering into employment with Milestone, in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Milestone, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Milestone, pursuant to Nasdaq Listing Rule 5635(c)(4).
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the treatment of symptomatic episodic attacks associated with AFib-RVR.
Contact:
Kevin Gardner kgardner@lifesciadvisors.com
